Mycenax Biotech (4726) — Cash Flow Reinvestment Rate

Latest as of March 2025: 7.62x

Mycenax Biotech (4726) has a Cash Flow Reinvestment Rate of 7.62x as of March 2025, reinvesting NT$108.92 Million (capex NT$84.30 Million plus investments NT$-24.62 Million) from operating cash flow of NT$14.29 Million. Check Mycenax Biotech cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

7.62x

(Capex + Investments) / Operating CF

Total Reinvested

NT$108.92 Million

Capex + Investments

Operating Cash Flow

NT$14.29 Million

TWD

Capital Expenditures

NT$84.30 Million

TWD

Mycenax Biotech Cash Flow Reinvestment Rate (2020–2020)

Historical reinvestment intensity for Mycenax Biotech across 1 annual periods. Explore 4726 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Mycenax Biotech (2020–2020)

Year-by-year capital reinvestment analysis for Mycenax Biotech. For live market cap and broader valuation context, see market cap of Mycenax Biotech.

Year	Reinvestment Rate	Total Reinvested (TWD)	Operating CF	Capex	YoY Change
2020	1.62x	NT$282.34 Million	NT$174.17 Million	NT$260.22 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow